Effect of Short-Term Vitamin D Correction on Hepatic Steatosis as Quantified by Controlled Attenuation Parameter (CAP).
J Gastrointestin Liver Dis. 2016 Jun;25(2):175-81. doi: 10.15403/jgld.2014.1121.252.cap.
Papapostoli I1, Lammert F1, Stokes CS2.
1Department of Medicine II, Saarland University Medical Center, Homburg, Germany.
2Department of Medicine II, Saarland University Medical Center, Homburg, Germany. caroline.stokes at uks.eu.
20,000 IU vitamin D daily for a week
20,000 IU vitamin D weekly for 6 months
Far better results would be expected if had done 1 or more of the following:
- Had used a type of vitamin D compatible with poorly functioning liver
- Had used a large loading dose (daily)
- Had used a larger maintenance dose (weekly)
- Had used dose sizes proportional to weight (obese need 2.5 X more)
See also VitaminDWiki
- Liver Inflammation (NAFLD) is prevented by Vitamin D – review May 2015
- Fatty Liver Disease in 40 percent of seniors (seniors often have low vitamin D)
- Non-alcoholic fatty liver disease (NAFLD) reduced somewhat by 50,000 IU vitamin D every 2 weeks – RCT Sept 2014
- Poorly functioning livers do not process vitamin D (Calcidiol is needed) – Sept 2014
- Search for Fatty Liver in VitaminDWiki 316 items July 2017
- Vitamin D-induced autophagy prevents steatosis Feb 2017
underlying mechanism: " 1,25(OH)2D3 is shown to protect against hepatic steatosis by inducing autophagy " Publisher wants $8 for the PDF
- Vitamin D and histologic severity of nonalcoholic fatty liver disease: A systematic review and meta-analysis Feb 2017, unsure
- Is Vitamin D an Independent Risk Factor of Nonalcoholic Fatty Liver Disease?: a Cross-Sectional Study of the Healthy Population Jan 2017, 30% more likely in men if < 20 ng of vitamin D - Free PDF online
- Low vitamin D status is associated with advanced liver fibrosis in patients with nonalcoholic fatty liver disease. Feb 2017, PDF costs $40
- NAFLD among Obese 2016 has the following chart
- Nonalcoholic Fatty Liver Disease (NAFLD)
SYMPTOMS: HowMed - before 2017
- Vitamin D: A new player in non-alcoholic fatty liver disease? Feb 2015
Download the PDF from VitaminDWiki
Note poor vitamin D response in first month, and Controlled Attenuation Parameter actually increased for a fraction of the people
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries. A meta-analysis has confirmed decreased serum 25-hydroxyvitamin D levels in NAFLD patients. This intervention study investigates whether vitamin D correction ameliorates hepatic steatosis.
We prospectively recruited 40 patients from an outpatient liver clinic with vitamin D deficiency (serum 25-hydroxyvitamin D < 20 ng/ml). Controlled attenuation parameter (CAP) during transient elastography quantified hepatic steatosis. Patients with significant liver fat accumulation were included, which was defined by a CAP value >/= 280 dB/m. Patients received 20,000 IU vitamin D/week for six months, while vitamin D status, liver function tests (LFTs), CAP and body composition were monitored.
The cohort comprised 47.5% women (age 54.9 +/- 12.1 years; BMI 29.5 +/- 3.0 kg/m2). Mean serum vitamin D level was 11.8 +/- 4.8 ng/ml. CAP decreased significantly from baseline (330 +/- 32 vs. 307 +/- 41 dB/m) during supplementation (P = 0.007). A mean CAP reduction relative to baseline was demonstrated at four weeks and three and six months: -5.3 +/- 13.8%; -6.0 +/- 14.6% and -6.4 +/- 13.0%, respectively. During these time points, restoration of serum vitamin D levels was observed (34.6 +/- 12.9, 36.3 +/- 10.2, 34.8 +/- 9.8 ng/ml; P < 0.0001). Liver function tests and body composition remained unchanged.
Hepatic steatosis, as assessed by CAP, significantly improves after only 4 weeks of vitamin D correction. Hepatic steatosis is a dynamic process, that can be monitored in the short-term using such non-invasive methods.